Table 4.
Multivariable Analysis of OS and PFS for hGBM Patients s/p SRT and TMZ with Known CDKN2A/B Deletion Status (n = 107)
| Characteristics | OS | P Value | PFS | P Value |
|---|---|---|---|---|
| Age at diagnosis | 0.99 (0.97–1.02) | .43 | 0.99 (0.97–1.01) | .36 |
| KPS | 0.96 (0.94–0.99) | .001 | 0.95 (0.94–0.97) | <.001 |
| Extent of resection | ||||
| GTR | Ref | Ref | ||
| STR | 1.48 (0.76–2.88) | .25 | 2.00 (1.14–3.50) | .02 |
| Biopsy | 2.79 (1.48–5.25) | .001 | 3.63 (1.97–6.70) | <.001 |
| Unmethylated MGMT | 1.59 (0.90–2.83) | .11 | 2.85 (1.66–4.87) | <.001 |
| CDKN2A/B deletion by NGS | 1.93 (1.08–3.43) | .03 | 2.02 (1.20–3.41) | .008 |
GTR, gross-total/near-total resection; hGBM, histological GBM; mGBM, molecular glioblastoma; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; SRT, standard-course RT; STR, subtotal resection; TMZ, temozolomide.